Alexander disease is a rare genetic disorder that progressively damages the nervous system, particularly affecting the brain’s white matter. Treatment focuses on managing symptoms and slowing disease progression, as there is currently no cure available. Both standard supportive therapies and innovative treatments being tested in clinical trials offer hope for improving quality of life for those affected by this challenging condition.

Understanding Treatment Goals and Approaches

When someone receives a diagnosis of Alexander disease, the main goal of treatment becomes managing the symptoms and maintaining the best possible quality of life for as long as possible. Because this condition progressively damages the protective covering around nerve fibers called myelin—a fatty substance that helps nerve cells communicate—the treatment approach must be carefully tailored to each patient’s specific needs and the stage of their disease.^[1]

Treatment strategies depend heavily on when symptoms first appear and which form of the disease a person has. For instance, infants who show symptoms before age two typically face different challenges than adults who develop the condition later in life. The neonatal form appears within the first month of life, the infantile form affects children before age two, the juvenile form strikes between ages two and thirteen, and the adult form can develop any time after the late teen years.^[2]

Medical societies and healthcare providers rely on established guidelines for treating Alexander disease, though these focus primarily on addressing individual symptoms rather than correcting the underlying genetic problem. At the same time, researchers worldwide are actively investigating new therapies through clinical trials, exploring innovative approaches that might one day slow or even halt the disease’s progression.^[3]

The disease occurs because of mutations in the GFAP gene, which instructs the body to produce glial fibrillary acidic protein. This protein normally supports brain cells called astrocytes, but when the gene is mutated, the protein accumulates abnormally. These accumulations form clumps called Rosenthal fibers, which damage the myelin and disrupt communication between nerve cells. This explains why treatment must address both the immediate symptoms patients experience and the longer-term effects of ongoing nerve damage.^[1]

Standard Treatment Approaches

Currently, there is no cure for Alexander disease, and standard treatment remains primarily supportive. This means healthcare providers focus on managing individual symptoms as they arise, rather than being able to stop the disease itself. The approach is often described as symptomatic and supportive care, designed to maintain comfort and function for as long as possible.^[6]

Seizures are among the most common and serious symptoms, particularly in infants and young children with Alexander disease. When seizures occur, doctors prescribe anticonvulsant medications to control them. These drugs work by stabilizing electrical activity in the brain, reducing the frequency and severity of seizure episodes. The specific anticonvulsant chosen depends on the type of seizures, the patient’s age, and how well they tolerate the medication. Common side effects of anticonvulsants can include drowsiness, dizziness, weight changes, and mood alterations, so doctors must carefully monitor patients to find the right balance between seizure control and quality of life.^[3]

Some children with Alexander disease develop hydrocephalus, a condition where fluid builds up inside the brain. When this happens, doctors may need to surgically place a shunt—a thin tube that drains excess fluid from the brain to another part of the body where it can be absorbed. This procedure can relieve pressure on the brain and reduce symptoms like headaches, vomiting, and vision problems.^[2]

Physical therapy plays a crucial role in managing muscle-related symptoms. Many patients experience spasticity—involuntary muscle stiffness and spasms—which can interfere with movement and cause discomfort. Physical therapists design exercise programs to maintain flexibility, strengthen muscles, and prevent joints from becoming fixed in abnormal positions. They may also recommend assistive devices like braces, walkers, or wheelchairs to help patients maintain mobility and independence.^[2]

Occupational therapy helps patients with daily activities that become difficult as the disease progresses. This might include strategies for eating, dressing, bathing, or using adaptive equipment to maintain independence. For children, occupational therapy can support developmental skills and school participation.^[8]

Speech and swallowing difficulties often develop, particularly in the juvenile and adult forms of Alexander disease. Speech therapists work with patients to improve communication and teach safe swallowing techniques to prevent choking and aspiration pneumonia. Some patients may eventually need feeding tubes if swallowing becomes too dangerous or if they cannot consume enough nutrition by mouth.^[2]

Nutritional support becomes increasingly important as the disease progresses. Many patients, especially infants and young children, experience failure to thrive and difficulty gaining weight. Dietitians can recommend high-calorie foods or supplements, and in severe cases, doctors may place a feeding tube directly into the stomach to ensure adequate nutrition.^[2]

The duration of treatment extends throughout the patient’s life, with regular adjustments needed as symptoms change. Families typically work with a team of specialists including neurologists, physical therapists, occupational therapists, speech therapists, dietitians, and sometimes orthopedic surgeons. This comprehensive approach, often called multidisciplinary care, ensures that all aspects of the disease are addressed.^[3]

Promising Research in Clinical Trials

While standard treatments provide symptom relief, they don’t address the root cause of Alexander disease—the accumulation of abnormal GFAP protein. Fortunately, researchers are now testing innovative therapies that aim to reduce this protein buildup and potentially slow disease progression. These investigations represent a significant shift from merely managing symptoms to potentially modifying the disease’s course.^[12]

The most advanced experimental treatment currently in clinical trials is an antisense oligonucleotide called zilganersen, also known by its research code name ION373. This therapy represents a sophisticated molecular approach designed to tackle the disease at its genetic source. The FDA has granted zilganersen fast track designation, a special status that accelerates the development and review process for treatments addressing serious conditions with unmet medical needs.^[14]

Zilganersen works through a targeted mechanism that interferes with the production of GFAP protein. Specifically, it is designed to bind to the messenger RNA that carries instructions from the mutated GFAP gene, preventing the cell from making excess amounts of the abnormal protein. By reducing GFAP levels, the therapy aims to prevent the formation of Rosenthal fibers and the subsequent damage to myelin and nerve cells. This approach doesn’t fix the underlying genetic mutation, but it could potentially slow or stabilize the disease by reducing the harmful protein accumulation.^[14]

The clinical trial testing zilganersen is a comprehensive Phase I-III study, meaning it combines early safety testing with later-stage effectiveness evaluation in a single, carefully designed protocol. This global trial is taking place across 13 sites in 8 countries, enrolling patients with Alexander disease aged 2 to 65 years. The study uses a randomized, double-blind design, which means participants are assigned by chance to receive either the experimental drug or a control treatment, and neither the patients nor the doctors know who receives which treatment during the main study period. This rigorous design helps ensure that any observed benefits truly result from the medication rather than other factors.^[14]

The trial structure includes a 60-week double-blind treatment period where patients receive either zilganersen or control treatment in a 2:1 ratio. This means twice as many participants receive the experimental drug compared to the control group. Following this initial period, all participants enter a 180-week open-label extension, during which everyone receives the active treatment. This design allows researchers to gather both controlled comparison data and longer-term safety and effectiveness information.^[14]

Researchers are measuring multiple outcomes to determine whether zilganersen helps patients. The primary endpoint—the main measure of success—is the percent change in the 10-meter walk test, which assesses how quickly and steadily patients can walk. Secondary measures include patients’ self-identified most bothersome symptom, overall impression of disease severity and change, motor function, quality of life, autonomic symptoms (like blood pressure regulation and digestion), and actual GFAP protein levels in the body.^[14]

Enrollment for this pivotal trial was completed in July 2024, and the pharmaceutical company Ionis has announced that topline results are anticipated in the second half of 2025. These results will be crucial in determining whether zilganersen becomes the first FDA-approved treatment specifically for Alexander disease, rather than just managing its symptoms.^[14]

The trial also includes a special sub-study for children under age two with Alexander disease, recognizing that this youngest group often faces the most severe form of the disease. This sub-study continued enrolling participants into 2025, reflecting the particular urgency of finding treatments for these very young patients.^[14]

Beyond zilganersen, researchers are exploring other innovative approaches in pre-clinical stages—meaning they are still being tested in laboratory settings and animal models before human trials can begin. These investigations are examining different therapeutic targets and strategies that might complement or provide alternatives to antisense oligonucleotide therapy.^[12]

One area of research focuses on understanding and targeting other proteins that accumulate abnormally in Alexander disease. Scientists have discovered that αB-crystallin, a small heat shock protein, also builds up in Rosenthal fibers alongside GFAP. Researchers are investigating whether reducing αB-crystallin levels or blocking its interaction with GFAP might help prevent the formation of these damaging protein clumps.^[12]

Another promising research direction involves gene therapy approaches. Scientists are working to develop treatments using AAV vectors (adeno-associated virus vectors)—modified viruses that can deliver genetic instructions into cells. The goal would be to introduce genetic material that either suppresses the production of mutant GFAP or produces molecules that counteract its harmful effects. While this technology is still in early research stages for Alexander disease, similar approaches have shown promise for other genetic neurological conditions.^[14]

Researchers are also investigating ways to enhance the brain’s natural protective mechanisms. One focus is on Nrf2, a protein that activates the body’s defense systems against cellular stress. Studies in animal models suggest that boosting Nrf2 activity might help cells cope with the damage caused by abnormal GFAP accumulation. Scientists are exploring whether drugs that activate this pathway could slow disease progression.^[12]

Additional research examines glutamate transporters, proteins that help remove excess glutamate—a chemical messenger in the brain—from the spaces between nerve cells. In Alexander disease, these transporters may not work properly, potentially contributing to nerve cell damage. Scientists are investigating whether enhancing glutamate transporter function might provide protective effects.^[12]

To develop and test these therapies, researchers have created animal models of Alexander disease. Mice have been genetically engineered to produce the same mutant forms of GFAP found in human patients. These mice develop Rosenthal fibers and experience seizures, though they don’t yet perfectly mimic all features of human disease. These animal models are essential for testing new treatments before they can be safely tried in human patients.^[11]

The research community has also established patient registries and natural history studies to better understand how Alexander disease progresses over time. These efforts help identify the best measures of disease activity and treatment response, which is crucial for designing effective clinical trials. The more researchers understand about the disease’s natural course, the better they can determine whether experimental treatments truly make a difference.^[16]

Approximately 90 percent of individuals with Alexander disease have identifiable mutations in the GFAP gene, but a small percentage do not have detectable GFAP mutations. This has led researchers to believe there may be other genetic or possibly non-genetic causes of Alexander disease that remain to be discovered. Understanding these alternative disease mechanisms could open additional treatment pathways.^[11]

Patient advocacy organizations play a crucial role in advancing research by raising funds, connecting families with trials, and ensuring that patient perspectives inform research priorities. Organizations like End Alexander Disease maintain contact registries that help researchers understand the full spectrum of the patient population and facilitate recruitment for clinical trials. These registries make the disease more visible to pharmaceutical companies and researchers, potentially accelerating treatment development.^[16]

Most Common Treatment Methods

• Symptomatic Management
  • Anticonvulsant medications to control seizures, the most common symptom requiring medical intervention
  • Surgical shunt placement for hydrocephalus when fluid buildup occurs in the brain
  • Medications and interventions tailored to individual symptoms as they develop
• Rehabilitation Therapies
  • Physical therapy to maintain flexibility, strengthen muscles, and prevent joint contractures in patients with spasticity
  • Occupational therapy to support daily activities and maintain independence with adaptive strategies and equipment
  • Speech and swallowing therapy to improve communication and teach safe swallowing techniques
• Nutritional Support
  • Dietary counseling and high-calorie supplementation for patients with growth faltering
  • Feeding tube placement when oral nutrition becomes inadequate or unsafe due to swallowing difficulties
• Experimental Antisense Oligonucleotide Therapy
  • Zilganersen (ION373), currently in Phase I-III clinical trials, designed to reduce excess GFAP protein production
  • Administered to patients aged 2 to 65 years across international trial sites
  • Aims to slow or stabilize disease progression by addressing the underlying protein accumulation
• Investigational Approaches (Pre-clinical)
  • Gene therapy using AAV vectors to suppress mutant protein production
  • Therapies targeting αB-crystallin and other proteins that accumulate in Rosenthal fibers
  • Drugs that activate Nrf2 to enhance cellular stress defenses
  • Treatments to improve glutamate transporter function and protect nerve cells